BrainCool AB (SE:BRAIN)
:BRAIN
BRAIN Stock Chart & Stats
kr0.58
kr0.19(9.74%)
At close: 4:00 PM EST
kr0.58
kr0.19(9.74%)
Day’s Range― - ―
52-Week Rangekr0.41 - kr1.86
Previous CloseN/A
Volume974.66K
Average Volume (3M)201.46K
Market Cap
kr229.03M
Enterprise Valuekr109.07M
Total Cash (Recent Filing)kr39.57M
Total Debt (Recent Filing)kr0.00
Price to Earnings (P/E)―
Beta0.25
Next Earnings
Jun 03, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.00
Shares Outstanding394,878,140
10 Day Avg. Volume223,544
30 Day Avg. Volume201,464
Financial Highlights & Ratios
PEG Ratio0.34
Price to Book (P/B)0.85
Price to Sales (P/S)4.14
P/FCF Ratio-2.66
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.02
Revenue Forecast (FY)kr73.00M
Bulls Say, Bears Say
Bulls Say
Debt-free Balance SheetZero reported debt and rising equity provide durable financial flexibility: lowers fixed financing costs, preserves borrowing optionality, and supports continued R&D and market rollouts. This capital structure reduces solvency risk while the company addresses commercialization and profitability gaps.
Historical Revenue ScalingMulti-year revenue growth demonstrates prior commercial traction and product adoption in acute care settings. That expanding top-line base reflects distribution, clinical uptake and market fit that can be leveraged to re-accelerate growth if margins and execution improve.
Improving Free Cash Flow TrendA reduction in cash burn suggests management initiatives or operating leverage beginning to take hold. If sustained, this trend can extend runway, reduce future funding frequency, and signal improved operational discipline—important for transitioning toward durable cash generation.
Bears Say
Persistent Operating LossesConsistent operating losses and a negative 2025 gross profit imply core product economics are not covering direct costs. This undermines sustainable profitability, limits reinvestment capacity, and means scaling revenue alone may not produce durable earnings without cost or pricing fixes.
Chronic Negative Cash FlowOngoing negative operating and free cash flow require external funding to sustain operations. Reliance on new capital risks dilution, raises execution pressure, and constrains long-term investments in sales, clinical studies, or regulatory work essential for medtech commercialization.
2025 Revenue ContractionA 17% YoY revenue decline after earlier growth indicates market or execution volatility. This weakens predictability of future cash flows, complicates planning for profitability, and may reflect competitive, adoption, or reimbursement headwinds that could persist absent corrective actions.
BrainCool AB News
BRAIN FAQ
What was BrainCool AB’s price range in the past 12 months?
BrainCool AB lowest stock price was kr0.41 and its highest was kr1.86 in the past 12 months.
What is BrainCool AB’s market cap?
BrainCool AB’s market cap is kr229.03M.
When is BrainCool AB’s upcoming earnings report date?
BrainCool AB’s upcoming earnings report date is Jun 03, 2026 which is in 67 days.
How were BrainCool AB’s earnings last quarter?
BrainCool AB released its earnings results on Feb 11, 2026. The company reported kr0 earnings per share for the quarter, the consensus estimate of kr0 by kr0.
Is BrainCool AB overvalued?
According to Wall Street analysts BrainCool AB’s price is currently Overvalued.
Does BrainCool AB pay dividends?
BrainCool AB does not currently pay dividends.
What is BrainCool AB’s EPS estimate?
BrainCool AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does BrainCool AB have?
BrainCool AB has 394,878,140 shares outstanding.
What happened to BrainCool AB’s price movement after its last earnings report?
BrainCool AB reported an EPS of kr0 in its last earnings report, expectations of kr0. Following the earnings report the stock price went down -3.2%.
Which hedge fund is a major shareholder of BrainCool AB?
Currently, no hedge funds are holding shares in SE:BRAIN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
BrainCool AB
BrainCool AB (publ), a medical device company, together with its subsidiaries, engages in the development, marketing, and sale of medical cooling systems for the healthcare sector in Sweden. The company offers products for medical cooling treatments for a range of diseases, including stroke, sudden cardiac arrest, oral mucositis, and migraine. It provides BrainCool and RhinoChill systems that facilitates rapid medical cooling treatment in an emergency setting and ensures the continuum of care; Cooral system provides medical professionals an easy way to reduce the risk of oral mucositis; and IQool system offers an easy-to-use intuitive interface, informative graphics, and an automatic feedback loop allowing clinicians to manage their patient rather than a device. The company was incorporated in 2010 and is based in Lund, Sweden.
Technical Analysis
Bactiguard Holding AB
―
C-Rad AB Class B
―
Acarix AB
―
Sedana Medical AB
―
Mentice AB
―